Aperio – 10 years later

One day in mid-2001 I was sitting in my office at Walter Reed Army Medical Center in Washington, DC when I was approached by a tall gentlemen with a South African accent who had with him about 10-12 sheets of paper in his left hand.  He introduced himself as Tim Marshall and asked if I had a few minutes to answer some questions.  At the time I shared the small office with a modest desk, microscope table, my microscope, PC and another equally modest (heavily used) desk used for a robotic telepathology system.

Tim had met with folks at the AFIP and then knowing of my interests in digital imaging, proceeded to ask me several questions that started with "What if" such as "What if you could scan a whole slide in 5 minutes?" or "What if it a computer could analyze a immunohistochemistry slide?"  or "What if you could look at a frozen section slide from a distance?"  He asked me 8 or 10 questions as I recall.  I did not know it at the time but as Tim was collecting this data from several folks, Dirk Soenksen, the Founder and CEO of Aperio was hard at work (perhaps still in his garage) perfecting the first generation Aperio scanner.  

A reliable hardware platform that could create a digital image of a 1x3 glass slide was born.  Each subsequent generation was better than its predecessor with added slide scanning capacities and capabilities for oil immersion & fluorescence microscopy.  

In 2001, the term "virtual microscopy" was popular.  Within a few years "digital pathology" was increasingly in use.  And Aperio from its inception has been the market leader in digital pathology.  One could go so far as to say they had to create the market based on their vision of the technology and what it offered to healthcare.  

They reported late last year that their install base consists of over 700 devices in more than 30 countries. I gather more slides are scanned on their devices in research and pharmaceuticals than anyone else. None of this would have happened without hardware that has been tried and tested with success.  

But for digital pathology as a market to succeed, the scanning hardware is only part of the solution. Software to incorporate managing, reviewing, analyzing and sharing these images is paramount. 

In a post about a week ago I mentioned how Aperio's latest release of their workflow software, Spectrum creates for tighter integration with clinical processes and diagnostic sign-out for pathologists.  The press announcement for Release 11 mentioned improvements to the product based on "broad usage and feedback from our customers".  This is an important process and one that Aperio may not have been focused on in recent years based on feedback from Spectrum users.  Positive to see the improvements are being made.  

It reminds me of a quote from somebody named Gates who wrote a book entitled "Business @ the Speed of Thought".  Allegedly this guy "Bill Gates" also started out in a garage.  He claims "Your most unhappy customers are your greatest source of learning".

Ask any practicing surgical pathologist one the of key drivers for adoption in the clinical space is making digital pathology as fast as glass for viewing.  This involves the requirement for an environment that provides the images as well as the clinical metadata from the LIS as well as bidirectional interfaces for order entry and result review. Again, the latest version is improving the software capabilities for the market leading digital pathology company today.  Clinical workflow processes are complex and vary widely from laboratory to laboratory.  

As I have heard from one software company in healthcare, "If you have seen one lab, you have seen one lab."  Add to that the nuances of hospitals and private labs, each unique and the nuances of individual pathologists and one can understand why these software applications have to be customizable to penetrate the market.  

Now, almost 10 years after those due diligence questions were posed to me, Aperio continues to provide superior scanning devices further enhanced by enabling software to facilitate clinical workflows.  

In the next 12 to 18 months it will be interesting to see how these improvements impact Aperio's business and how some of the newer vendors will be perceived with increasing focus on optimizing clinical workflow through software.

 

 

 

 

 

Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests

Definiens continues to demonstrate why their image analysis technology continues to meet increasing challenges and levels of sophistication.  Increasingly the road to the accurate diagnosis and appropriate treatments and potential cures for cancer are paved with image analysis applications that meet the challenges with increasingly complex data sets and Definiens continues to set themselves apart.
 
Multi-color fluorescence slides analyzed by Definiens Tissue Studio to provide clinicians with more complete understanding of disease state

MUNICH and DANVILLE, Pa., April 6, 2011 /PRNewswire/ -- Definiens, the number one Health Image Intelligence™ company, and Cernostics, a life sciences firm specializing in advanced cancer diagnostics, today announced a partnership to develop a unique multiplexed assay tool for the diagnosis of cancer. Cernostics will apply Definiens' image analysis technology to develop new molecular diagnostic tests for the treatment of a variety of cancer types.

Cernostics is using Definiens Tissue Studio™ to develop its cancer diagnostic test, which relies on highly multiplexed panels of fluorescence biomarkers, with the final goal to deploy the solution in the clinical routine. Definiens Tissue Studio enables pathologists to analyze cancers on the cellular and sub-cellular level. Rapid and accurate quantification of cancer characteristics will provide the Cernostics research team with data on which to build and deploy cancer diagnostic tests.

Unlike some approaches that rely on single-biomarker expression, Cernostics takes a systems approach to tumor analysis, evaluating immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. This can help clinicians better understand disease subtypes and help them choose the course of treatment most suited to each patient's disease state.

"The partnership between Definiens and Cernostics will apply powerful technology to the field of oncology diagnostics," said Thomas Heydler, CEO of Definiens. "Definiens Tissue Studio is uniquely able to evaluate multiple channels from a single sample, providing accurate data to support clinical decisions and help clinicians apply the best treatment for each patient."

"The collaboration with Definiens will enable Cernostics to accelerate development of its pipeline of systems biology-based diagnostic, prognostic and predictive tests. Cernostics is in a unique position to provide unsurpassed solutions for tissue analysis and cancer diagnosis and the well validated Definiens software is a key component for extracting precise image measurements," said Michael Hoerres, CEO of Cernostics.

To support its development of oncology diagnostic technology, Cernostics is working closely with Geisinger Health System, a $2.3 billion integrated health services organization based in Pennsylvania. Supported by Geisinger, Cernostics gains access to a clinical setting on which to create and validate pathology solutions, including a large tumor bank linked to well-annotated, deep and longitudinal clinical information.

About Definiens 

Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company's software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources, supporting better decisions in research, diagnostics and therapy. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports personalized medicine and aims to significantly improve the quality of patients' lives.

Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at http://www.definiens.com.

Definiens – from images to clinical decisions.

Definiens, Definiens Cognition Network Technology, Definiens Cellenger, Definiens Tissue Studio, Definiens LymphExpert, Enterprise Image Intelligence, Health Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens

About Cernostics Inc.

Cernostics is integrating quantitative pathology, advanced informatics and electronic medical record (EMR) management to create clinically-driven pathology solutions to improve individualized patient care. Cernostics focuses on TissueCipher Pathology (TCP™), a proprietary approach to integrating digital imaging pathology, highly multiplexed panels of fluorescence biomarkers, informatics and EMR systems for faster, better, less expensive pathology testing and improved individualized patient treatments. http://www.cernostics.com.

Press Contacts

Definiens
Martin Baatz
E-mail: mbaatz@definiens.com

Ricochet Public Relations
John Abrashkin
Phone: +1 212 679 3300 x121
jabrashkin@ricochetpr.com

Cernostics
Dan Carr
Phone: +1 570 271 7441
info@Cernostics.com

 

SOURCE Definiens

RELATED LINKS
http://www.definiens.com

Managing Multiple Generations in Your Lab: Proven Methods to Motivate Gen X, Gen Y, and Baby Boomers in the Same Workplace

How to build teamwork, boost productivity,
and enhance harmony 
in your lab’s multi-generational workforce

Jeff Smithjustin clark

YOUR PRESENTER:

Jeff Smith, Principal, Titan Group

Justin M. Clark (Moderator), Director of Operations, THE DARK REPORT

 

LIVE Event April 20th – Register NOW!

In today’s modern laboratory, four different generations of employees now work side by side. But that doesn’t mean your lab is a harmonious or productive place to work. Workplace relations can sometimes become volatile when, for example, a 22-year-old Gen-Xer fresh out of college ends up working alongside a highly experienced 64-year-old baby-boomer medical technologist.

Find out how to tackle the tough issues you face when managing four generations in your laboratory when you join THE DARK REPORT and DarkDaily.com on Wednesday, April 20, 2011 for “Managing Multiple Generations in Your Lab: Proven Methods to Motivate Gen X, Gen Y, and Baby Boomers in the Same Workplace.”

Jeff Smith, your leader for this informative session, will start by explaining the unique attributes of the four generations: The silent generation (born 1925-1945), baby boomers (born 1946-1964), Gen X (born 1965-1980) and Gen Y (born 1981-2003). Each of these generations presents its own management challenges. You’ll get a checklist of management do’s and don’ts and learn the latest techniques for supervising multi-generational staff that will help you address these challenges.

Smith is well qualified to guide you through the challenges and opportunities of managing a laboratory workforce. At Carilion Laboratories, he ran the human resources department while the parent health system was actively transforming the management culture and work environment in the laboratory division.

You’ll gain a better understanding of the expectations and motives of each generation. Find out how to identify common sources of conflict and even outright refusals to work that can arise as different generations in the same department react to the different values of their co-workers.

Smith will also provide effective management methods that work-proven techniques for boosting your credibility with the members of each generation. More important, these approaches encourage teamwork, workplace harmony, and the shared sense of purpose that your laboratory staff needs to perform at peak productivity.

If you’re still managing your workforce the way you always have, it’s time to rethink that strategy. Each of the four generations now working in your laboratory approaches work differently. Whether it’s how they want feedback, how they connect to your organization or how they access information, their view of the world and their jobs is unique. Attempting to manage them with a single approach is likely to result in conflict and a lack of productivity that no clinical laboratory or pathology group can afford.

Get practical, applicable techniques for coaching and motivating every generation on your staff. You’ll develop better connections with all your workers that will translate into improved communications, increased job satisfaction, and better overall performance for your lab.

The new multi-generational workforce is the wave of the future and it’s changing the way businesses manage their employees. Find out what it takes to manage four generations of workers in your lab when you register to attend the latest Dark Report audio conference “Managing Multiple Generations in Your Lab: Proven Methods to Motivate Gen X, Gen Y, and Baby Boomers in the Same Workplace” on Wednesday, April 20, 2011.

And remember that you can have everyone on your lab team participate with you. For just one registration, you can all listen, learn, and get personalized answers to questions about your lab’s unique needs.


THE DARK REPORT AUDIO CONFERENCE AT A GLANCE

 

DATE: Wednesday, April 20, 2011

TIME: 1 p.m. EDT; 12 p.m. CDT; 11 a.m. MDT; 10 a.m. PDT

COST: $195 per dial-in site (unlimited attendance per site) through 4/8/11; $245 thereafter

TO REGISTER NOW: Click here or call 1-800-560-6363 toll-free



For one low price—just $195 
(through 4/8/11, $245 thereafter)—you and your entire team can take part in this fast-paced, insightful audio conference. Best of all, you’ll be able to connect personally with either of the panelists when we open up the phone lines for live Q&A.

Here’s just some of what you’ll learn during this in-depth 90-minute audio conference:

  • How to define the four generations: silent generation, baby boomers, generation X, generation Y.
  • The different attitudes that each generation has about work.
  • Tips for motivating all generations of employees in your lab-even the youngest ones.
  • How to encourage employees from different generations to respect and communicate with each other.
  • Practical advice on handling challenging conversations with the most difficult employees in your laboratory.
  • Effective ways to motivate talented employees who don’t show interest in advancement or job growth.
  • Proven methods for handling your toughest management problems while respecting the generational differences of your staff.
  • The secret to reversing the attitudes of lab staffers who are resistant to change or who have a sense of entitlement.

…and much more!


How to Register Now:

1. Online
2. Call toll free: 800-560-6363.


Your audio conference registration includes:

  • A site license to attend the conference (invite as many people as you can fit around your speakerphone at no extra charge)
  • A downloadable PowerPoint presentations from our speakers
  • A full transcript emailed to you soon after the conference
  • The opportunity to connect directly with the speaker during the audience Q&A session

Register Now! Or for more information, call us toll-free at 800-560-6363

Distinguished Faculty:
 

Jeff Smith has more than 20 years of experience as an executive in human resources and operations roles for both for-profit and not-for-profit organizations. He works with Slone Partnersproviding leadership development for lab professionals and teaches for Titan Management University. Previously, Mr. Smith worked for Capital One and Carilion Clinic. He was Director of Human Resources for Carilion Labs and helped drive culture change, implemented succession planning and created coaching tools for laboratory leaders. He uses a collaborative approach with his clients to help them determine their vision and then identify a plan to help them achieve that vision in their professional and personal lives. His HR expertise includes: organizational development, organizational change, succession planning, executive coaching, teambuilding, leadership development and recruiting. Mr. Smith graduated cum laude with a BBA from James Madison University in management and history. He also holds an MA from George Washington University in Human Resource Development. Additionally, Mr. Smith graduated from Georgetown University with an Executive Coaching and Leadership Certificate and became a fellow of the advisory board in 2006. He is certified as a professional coach (PCC) by the International Coaching Federation.

ACCENT® Continuing Education Credit
The American Association of Clinical Chemistry (AACC) designates this program for a maximum of 1.5 ACCENT® credit hours towards the AACC Clinical Chemist’s Recognition Award. AACC is an approved provider of continuing education for clinical laboratory scientists in the states of California, Florida, Louisiana, Montana, Nevada, North Dakota, Rhode Island, and West Virginia.

 

Leica and SlidePath got it right

Last month I was fortunate to see a demo of Leica's SCN400 scanner and their image management system provided by SlidePath's Digital Imaging Hub.

See: http://www.leica-microsystems.com/products/light-microscopes/clinical/upright-microscopes/details/product/leica-scn400-2/

See: http://www.leica-microsystems.com/products/digital-pathology/digital-pathology-software/

In short, the images were of very high quality with reasonable scan times at 40x with reproducible high throughput and fast image review.  A number of images were uploaded to one of the data centers and reviewed remotely with ease with a number of web browsers without difficulty.  

Despite being one of the last traditional microscope vendors to enter the digital pathology space, their solution complete with image management and image analysis provided by SlidePath makes Leica the single best out-of-the-box (OK it was a lot of boxes) solution I have seen in over 10 years.  

And a reasonable price point to match.

Having never seen their scanner and reading the reviews I thought the images would be high quality but we would have the usual and customary issues when these systems are first implemented.  None.  The system scanned the slides without incident and identifying them was simple through large thumbnails and conspicuous reference identifiers.  

Although it did take longer than one would like to upload the images to a remote data center, the ability to see those images present quickly and refresh quickly with no pixelation or delay made up for the upload time.  

I was particularly impressed with the ability to rotate the images and link multiple slides to one another to view comparable fields or multiple slides from the same case (i.e. aspirate slide and bone marrow section).

As should be the case with any demonstration, your slides should be used.  Determine if there are going to be issues with slides themselves, coverslips, stain quality, etc... For this demo we intentionally picked average to below average quality slides from a stain perspective, complete with off-center coverslips and large ink dots on one particular slide.

Despite our best attempt, the images were some of the best I have seen in that they were true to form but were not compromised in any way by the poor coverslipping or ink dots on the slide.  For once, the tissue was sharply in focus and needed minimal adjustment, which is possible and the ink dots were present but not a deterrent.  

Add to that SlidePath's image analysis tools on those images from a web-based platform and you are up and running.  

We also looked at a few cytology slides, mostly gynecologic cytology and a single fine needle aspiration slide of moderate cellularity and the scanner again passed the test.  As is the case with cytology specimens, three dimensional groups can be an issue, as they are with light microscopy, but the images provided comparable clarity.  I have actually found cytology images to be "crisper" with whole slide imaging than with conventional light microscopes and this was true of Leica's scanner as well.

The combination of Leica's long history with high-end optics and SlidePath's proven track record with their Digital Image Hub makes for a perfect digital pathology solution for clinical or research use.  

If you are considering a digital pathology "system" you would be wise to consider this solution in your evaluation.

 

Do you have a degree in mechanical engineering or EE and would like to see the world? Phlips UFS Engineer may be position for you


At Philips, we believe technology can be advanced and simple at the same time. Designed around the way you live and work. Technology that makes sense. This is how we touch people's lives all over the world. Whether it’s the lighting that guides people on their way home or the intelligent products people have come to love both in and outside the family. You can be part of that experience. At Philips, you'll touch lives every day.

 

UFS Engineer - Digital Pathology Maintenance (APAC) - Job ID: 77163
(Singapore)

Responsibilities:

 

The UFS Engineer is responsible for maintaining and repairing of the Digital Pathology Ultra Fast Scanner (UFS).
  • On-site support in solving customer problems on UFS
  • Execution of the action plans and together with the Customer Service Manager, chase the problems to closure
  • Repair of the UFS by replacing mechanical and electronic parts
  • Adjusting the UFS parts mechanically
  • Calibrating UFS  by using service software on a service PC
  • Reporting of actions back to the Customer Service Manager
  • Performing planned maintenance on the scanner
  • Continuously improves the customer service processes

 

Requirements:

  • Diploma or Degree in Mechanical Engineering or Electronics
  • 4+ years experience in Customer Service, preferably in Healthcare
  • Experience in contacts with customers
  • Experience in maintaining medical devices/equipments
  • Knowledge in mechanics, electronics and computers
  • Able to travel 40% – 60% across APAC
  • Languages: English and Mandarin in order to liaise with Mandarin speaking associates

 

 

Qualified candidates may submit their resumes outlining qualifications, experience, current and expected salaries online athttp://www.philips.com/careers

(Select 'Career Search' and enter relevant Job ID).

 

 

logo

 

 

Healthcare leaders hail selection of Mostashari to lead ONC

Courtesy of ModernHealthcare.com:

Members of the healthcare community are praising the selection of Dr. Farzad Mostashari as the next head of the Office of the National Coordinator for Health Information Technology at HHS.

Mostashari succeeds Dr. David Blumenthal as head of the ONC


Mostashari previously was deputy national coordinator for programs and policy at the ONC. He joined the ONC in July 2009, according to the ONC's website.

Read more: Healthcare leaders hail selection of Mostashari to lead ONC

In other news also courtesy of same site, HHS Secretary Kathleen Sebelius has canceled her plans to speak at the American Hospital Association's annual meeting on April 11, as HHS and other agencies prepare for a federal government shutdown.

Read more: Looming shutdown keeps Sebelius away from AHA meeting

Really?  ONC can go on with business as usual with a vision for a new leader but its parent agency, HHS cannot? Huh?

 

i-Path Diagnostics Commissioned to Develop Software for the Northern Ireland Biobank

New Northern Ireland Biobank will be central to cancer research locally, nationally and internationally

i-Path Diagnostics is being has been chosen as the cloud based digital pathology platform to study human tissue samples, improve understanding of cancer, develop new drugs and identify patients who will benefit from drugs.

£1.9m of funding has been secured to establish Northern Ireland’s first comprehensive cancer tissue collection aimed at supporting local, national and international cancer research.   i-Path Diagnostics will develop the Northern Ireland Biobank’s  IT systems to support and manage this new bank of cancer tissue samples. 

Thousands of samples will be collected over the next few years together with extensive clinical, treatment, response and survival data. 

Des Speed, CEO of i-Path Diagnostics said: “We are very pleased to be playing a central role in the creation of this new facility in Northern Ireland.  The new Biobank will play a crucial role in diagnosis and the development of the new treatments and therapies for cancer that we hope will have a positive impact on the lives of many people in the years ahead.” 

The i-Path software will store, organize and manage all virtual slides, giving cancer researchers within Northern Ireland and across Europe the ability to search for the right samples and retrieve tissues to aid new scientific discoveries. 

The system will also give researchers across Europe access to high resolution digital images of the tissue samples remotely using i-Path’s proprietary web-based software.  

i-Path’s world-class technology removes the need to post microscopic slides to different locations and creates opportunities for remote analysis of tissues and high throughput computerised analysis of tissue biomarkers, and remote TMA management and manual scoring. 

The Northern Ireland Biobank Scientific Lead, Dr Jackie James said: "This repository of tumour samples is essential for the development of new targeted therapies in cancer and will support the local, national and international development of  Stratified Medicine". 

i-Path will work with the local cancer research community to develop a resource that will underpin cancer research for years to come.

 

Olympus Licenses Digital Pathology Patents to Leica Microsystems

Busy news day at the end of Q1 2011.

CENTER VALLEY, Pa., March 31, 2011 /PRNewswire/ -- Olympus America Inc. and Leica Microsystems GmbH of Wetzlar, Germany have signed a nonexclusive worldwide licensing agreement allowing Leica to access an extensive portfolio of patents held by Olympus in the field of digital pathology and virtual microscopy. The patents included in the licensing deal cover methods and equipment for creating, storing and delivering virtual microscopy slides. The technology enables individuals to view and share high-resolution virtual microscopy images over the Internet.

"We've seen interest in digital slide scanning grow rapidly over the past few years," said Osamu Joji, Group Vice President and General Manager of Olympus America's Scientific Equipment Group. "Olympus is the holder of these important patents, and we feel it is vital to allow broad access to these technologies in order to advance the field of pathology. Ultimately, we hope that implementing these technologies will help enhance healthcare for patients around the world."

"We believe digital slide scanning will be the fastest growing segment in microscopy for years to come. This license agreement will enable us to further expand our offering in this space, and to provide our customers around the world with a complete solution from digital scanning of microscopy slides to the handling and management of digital pathology data," said Stefan Traeger, Managing Director of Leica's Life Science Division.

The companies are not making specific terms and conditions of the agreement public.

About Olympus America Inc., Scientific Equipment Group

Olympus America Scientific Equipment Group provides innovative microscope imaging solutions for researchers, doctors, clinicians and educators. Olympus microscope systems offer unsurpassed optics, superior construction and system versatility to meet the ever-changing needs of microscopists, paving the way for future advances in life science.

About Olympus

Olympus is a precision technology leader, designing and delivering innovative solutions in its core business areas: Medical and Surgical Products, Life Science Imaging Systems, Industrial Measurement and Imaging Instruments and Cameras and Audio Products. Olympus works collaboratively with its customers and affiliates worldwide to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. 

Olympus serves the healthcare field with integrated product solutions and financial, educational and consulting services that help customers to efficiently, reliably and more easily achieve exceptional results. Olympus develops breakthrough technologies with revolutionary product design and functionality for the consumer and professional photography markets, and also is the leader in gastrointestinal endoscopy and clinical and educational microscopes. For more information, visit http://www.olympusamerica.com.

 

About Leica Microsystems

Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company's history was marked by unparalleled innovation on its way to becoming a global enterprise. Its historically close cooperation with the scientific community is the key to Leica Microsystems' tradition of innovation, which draws on users' ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division, Biosystems Division and Medical Division.

Leica Microsystems Biosystems Division, also known as Leica Biosystems, offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory. The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.

 

 

SOURCE: Olympus America Inc.

 

CMS Releases Proposed Rule for ACOs

HHS Secretary Kathleen Sebelius and CMS Administrator Donald M. Berwick, MD, this morning announced the release of the proposed rules for implementation of accountable care organizations (ACOs), as required under the health care reform law.

“These rules will help teams of doctors form ACOs…and in return, they will be able to share in savings that come from coordinating care and improving the quality of health,” said Secretary Sebelius during a telephone press event announcing the rule’s release. She added that CMS estimates ACOs could save Medicare between $510 million and $960 million over the next three years, net of provider savings payments.

Coming in slightly over 400 pages, the proposed rule will be open for comments for 60 days, and CMS officials will be gathering stakeholder feedback at listening sessions held throughout the country in the coming months. The College is currently analyzing—and will provide feedback to CMS—on the rule’s impact on pathologists. CMS is expected to publish a final rule later this year.

The proposed rule includes 65 quality measures, which Dr. Berwick detailed in a New England Journal of Medicine column, also published online this morning. In addition, the Federal Trade Commission (FTC) released an anti-trust document this morning to accompany the CMS proposed rule. In the Proposed Antitrust Enforcement Policy Statement Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program, the FTC outlines certain safe harbors and related information allowing providers to form integrated health care delivery systems without conflicting with the antitrust laws.

 

Ventana Medical Systems, Inc. Launches Virtuoso Software for Digital Pathology

Ventana acquired BioImagene last June.  This is the first of likely many improvements on their digital pathology platform.

Latest version provides pathologists with superior case management and telepathology capabilities

TUCSON, Ariz., March 31, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc., a member of the Roche Group, announced today the availability of its next generation Virtuoso digital pathology application software. 

(Photo: http://photos.prnewswire.com/prnh/20110331/LA74593)

The new version of Virtuoso software expands pathologists' workflow capabilities with features that deliver additional gains in efficiency, collaboration, and productivity. Pathology labs worldwide will realize significant value and workflow improvements with the upgraded software enhancements including:

20110331125931ENPRNPRN-VENTANA-SOFTWARE-90-1301576371MR Pathologist workflow enhancements – ability to create a worklist that gives pathologists the flexibility to work on cases in their desired order; the option to include gross images in case reports; synchronized image viewing that is ideal for comparing serial sections on a case with different markers; and role-based portals to ensure that individual needs are met for each person in the pathology laboratory workflow.

Telepathology enhancements – the capability to conveniently share cases for review by other pathologists; a real-time collaboration feature enabling simultaneous peer reviews; and case review guidance for residents for educational purposes.

User Interface (UI) enhancements – context-sensitive toolbars for a faster and more intuitive viewer experience and an interactive UI that allows microscope-like panning and zooming on images.

Christopher Cestaro, Lifecycle Leader, Advanced Workflow, Ventana Medical Systems, Inc., commented, "Digital pathology is transforming the practice of pathology in ways that will significantly impact the delivery of healthcare in the future. Ventana digital pathology solutions fully leverage our strengths in high quality staining platforms, assays, and workflow solutions such as VANTAGE, to deliver a complete end-to-end solution for pathology laboratories. Our global leadership in the pathology market ensures that our customers continue to have access to the most innovative products and solutions."

The new features of the Virtuoso 5.0 software will improve the pathologist's ability to manage and share cases, and collaborate in real time. Virtuoso works with the VENTANA iScan Coreo Au scanner to deliver a comprehensive digital pathology solution from image acquisition to case management, report customization, and more.

Ventana test systems are for in vitro diagnostic use for specific clinical applications, and are intended for research use only for other applications.

About Ventana Medical Systems, Inc

Ventana Medical Systems, Inc. ("VMSI") develops, manufactures, and markets instrument/reagent systems that automate tissue preparation and slide staining in clinical histology and drug discovery laboratories worldwide. The Company's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. VMSI's drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds. In addition, the Company offers premier workflow solutions designed to improve laboratory efficiency, providing safeguards to enhance the quality of healthcare. Ventana Medical Systems, Inc. is a wholly-owned member of the Roche Group. For more information on Ventana Medical Systems, Inc. visit http://www.ventana.com.

For further information, please contact:
Jacquie Bucher
Ventana Media Relations
520-877-7288  jacquie.bucher@ventana.roche.com

SOURCE Ventana Medical Systems, Inc.

Copyright (2011) PR Newswire. All Rights Reserved

Advanced Cell Diagnostics And Definiens Partner To Develop Tool For Quantitative Biomarker Analysis

From DigitalPathologyInsigts.com:

HAYWARD, Calif. and MUNICH, March 31, 2011 /PRNewswire/ — Advanced Cell Diagnostics (ACD), a technological leader in molecular pathology, and Definiens, a leading provider for biomedical image and data analysis, announce today a strategic partnership to develop image analysis applications that will enable researchers to accurately quantify specific RNA molecules within individual cells in routine clinical specimen. The partnership will build on ACD’s RNAscope platform and add new specialized image analysis solutions that will automatically process and analyze images from RNAscope assays. The software system will significantly enhance the utility of RNAscope-based diagnostic tests for personalized medicine. ACD will demonstrate the  technology at booth #413 of the 2011 AACR conference in Orlando, FL on April 3 – 6.

ACD’s RNAscope is a novel and proprietary RNA in situ hybridization (ISH) method that can detect and quantify virtually any expressed gene at single molecule sensitivity in individual cells in all major biological specimen types, including cell lines, PBMC and FFPE tissue sections. As the most clinically robust RNA ISH assay available, RNAscope enables the fastest path from genomic discovery to validated biomarkers and clinical diagnostic tests.

Under the agreement, Definiens will develop a unique and proprietary image analysis application for ACD that provides users with powerful analysis capabilities. Definiens software, based on its Definiens XD framework, offers users with accurate, robust and scalable image analysis solutions for a wide range of histology analysis.

“The partnership between Advanced Cell Diagnostics and Definiens will combine two powerful technologies in the promising field of RNA biomarker identification and development,” said Thomas Heydler, CEO of Definiens. “With our image intelligence technology’s superior accuracy and multiplexing capabilities, Definiens is uniquely suited to help Advanced Cell Diagnostics create powerful RNA assays that can further support personalized medicine initiatives around the world.”

“This advanced image analysis solution will bring objective and accurate quantification to RNAscope and enable a new generation of diagnostic applications such as circulating tumor cell detection and molecular analysis. For the first time, gene expression can be measured quantitatively at single cell resolution and interpreted by pathologists within histopathological context,” said Dr. Yuling Luo, Founder, President and CEO of ACD.

About Advanced Cell Diagnostics (http://www.acdbio.com)

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management.

About Definiens

Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company’s software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources, supporting better decisions in research, diagnostics and therapy. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports personalized medicine and aims to significantly improve the quality of patients’ lives.

Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at http://www.definiens.com.

Definiens – from images to clinical decisions.

Aperio making strides

In January Aperio released Version 11 of their software, Spectrum.  The press release noted:

""Release 11 adds and expands key features of our system that address the needs of pathologists in both clinical and research environments, based on broad usage and feedback from our customers,” said Dirk G. Soenksen, CEO of Aperio. “Through our ongoing development efforts we continue to supply the pathology community with the most comprehensive patent-protected digital pathology solutions available to help inform better patient care decisions.”

Spectrum consolidates pathology cases, projects, specimens and slides into an integrated source with 24/7 anytime access, eliminating the transfer of glass slides, improving efficiency and streamlining pathology workflow and analysis.

Spectrum’s secure, customizable workflow has made it the digital pathology information management solution of choice for leading global institutions including ARUP Laboratories and Memorial Sloan Kettering."

I think this is key to the adoption of digital pathology - tighter integration that is workflow driven and consolidates information.  I have found this to be a problem with past versions of Spectrum that keeps on getting better and better from earlier versions.  One of the keys to success in this space is getting the process as close to looking at a glass slide (for now) to aid adoption.  Additional mouse clicks, multiple screens, applications or poor integration with LIS data will impede mass adoption.

Additionally, Aperio recently launched, in partnership with USCAP an extensive collection from Dr. Juan Rosai, recognized as one of the foremost surgical pathologists of our time.

From the Aperio website: 

This comprehensive collection of Surgical Pathology Seminars (1945 to the present) comprises digital images of original slide material of nearly 20,000 cases originally presented at approximately 1500 pathology seminars. The collection includes clinical history summaries, discussions, and diagnoses by yesterdays authorities with updates and comments by Dr. Rosai and other contemporary experts. Pathologist spanning the globe can access the collection to learn about the evolution of surgical pathology thinking, as described and discussed at pathology society meetings, individual medical centers, and pathology groups over the past 60 years.

Juan Rosai makes freely available to the International pathology community the digital version of this historical collection through a partnership with the USCAP and Aperio.

  • Gain insight into the evolution of surgical pathology thinking
  • Browse original material that led to discoveries of new entities and concept proposals
  • Access case slides, discussion notes, and speaker biographies
  • View updated diagnostic interpretations of the seminar cases
  • Access resource for decision support, self-study, and publications

This is covered on USCAP TV:

    I reviewed some of the old cases and the images are excellent, complete with aging cover slip media but nonetheless the diagnostic features are evident on the tissue itself.  The images launched quickly and refreshed quickly within my web browser.  Several cases were scanned at 20x that I thought would be better with 40x scans and several cases with documentation I tried failed to open the pdf.  I presume this has the accompanying clinical information and any follow-up information with supporting literature from the original slide conferences they are a part of but I could not tell.

    Recently, the USPTO affirmed Hamamatsu's patent for slide scanning with remote viewing as reported by several news sources.  You may recall in June 2009, Aperio filed suit against Hamamatsu and others.  My understanding is that this issue has been settled by the parties.  

    Nonetheless, lawsuits take time and resources away from innovation and I wonder what impact, if any, this patent re-issue may mean for companies such as Aperio and others.  

     

     

       

       

      Proceedings of the 10th European Congress on Telepathology and 4th International Congress on Virtual Microscopy Proceedings

      from The 10th European Congress on Telepathology and 4th International Congress on Virtual Microscopy
      Vilnius, Lithuania. 1-3 July 2010
      Edited by Klaus Kayser, Arvydas Laurinavicius and Gian Kayser
      Sponsorship for publication of these proceedings has been provided by the International Academy of Telepathology (IAT), COST-Action IC0604, EU Verein Förderung des Biol.-Techn. Fortschritts in der Medizin, e.V., Heidelberg, DiagnomX GmbH.

      Proceedings    
      Virtual telepathology in Egypt, applications of WSI in Cairo University
      Essam Ayad
      Diagnostic Pathology 2011, 6(Suppl 1):S1 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Localization of Eosinophilic Esophagitis from H&E stained images using multispectral imaging
      Pinky A Bautista, Yukako Yagi
      Diagnostic Pathology 2011, 6(Suppl 1):S2 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Towards a computer aided diagnosis system dedicated to virtual microscopy based on stereology sampling and diffusion maps
      Philippe Belhomme, Myriam Oger, Jean-Jaques Michels, Benoit Plancoulaine, Paulette Herlin
      Diagnostic Pathology 2011, 6(Suppl 1):S3 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Intelligent security and privacy solutions for enabling personalized telepathology
      Bernd Blobel
      Diagnostic Pathology 2011, 6(Suppl 1):S4 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Digital pathology evaluation of complement C4d component deposition in the kidney allograft biopsies is a useful tool to improve reproducibility of the scoring
      Ernesta Brazdziute, Arvydas Laurinavicius
      Diagnostic Pathology 2011, 6(Suppl 1):S5 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      COST Action “EuroTelepath”: digital pathology integration in electronic health record, including primary care centres
      Marcial García Rojo, Ana Morillo Castro, Luis Gonçalves
      Diagnostic Pathology 2011, 6(Suppl 1):S6 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
      S Fasanella, E Leonardi, C Cantaloni, C Eccher, I Bazzanella, D Aldovini, E Bragantini, L Morelli, LV Cuorvo, A Ferro, F Gasperetti, G Berlanda, P Dalla Palma, M Barbareschi
      Diagnostic Pathology 2011, 6(Suppl 1):S7 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Traditional microscopy instruction versus process-oriented virtual microscopy instruction: a naturalistic experiment with control group
      Laura Helle, Markus Nivala, Pauliina Kronqvist, Andreas Gegenfurtner, Pasi Björk, Roger Säljö
      Diagnostic Pathology 2011, 6(Suppl 1):S8 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      How to measure diagnosis-associated information in virtual slides
      Klaus Kayser, Jürgen Görtler, Stephan Borkenfeld, Gian Kayser
      Diagnostic Pathology 2011, 6(Suppl 1):S9 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Interactive and automated application of virtual microscopy
      Klaus Kayser, Jürgen Görtler, Stephan Borkenfeld, Gian Kayser
      Diagnostic Pathology 2011, 6(Suppl 1):S10 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      E-education in pathology including certification of e-institutions
      Klaus Kayser, Robert Ogilvie, Stephan Borkenfeld, Gian Kayser
      Diagnostic Pathology 2011, 6(Suppl 1):S11 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Grid computing in image analysis
      Klaus Kayser, Jürgen Görtler, Stephan Borkenfeld, Gian Kayser
      Diagnostic Pathology 2011, 6(Suppl 1):S12 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Five years of experience teaching pathology to dental students using the WebMicroscope
      Janusz Szymas, Mikael Lundin
      Diagnostic Pathology 2011, 6(Suppl 1):S13 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Quality evaluation of virtual slides using methods based on comparing common image areas
      Slawomir Walkowski, Janusz Szymas
      Diagnostic Pathology 2011, 6(Suppl 1):S14 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Color standardization and optimization in Whole Slide Imaging
      Yukako Yagi
      Diagnostic Pathology 2011, 6(Suppl 1):S15 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Distributed computing in image analysis using open source frameworks and application to image sharpness assessment of histological whole slide images
      Norman Zerbe, Peter Hufnagl, Karsten Schlüns
      Diagnostic Pathology 2011, 6(Suppl 1):S16 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Recent advances in standards for collaborative Digital Anatomic Pathology
      Christel Daniel, François Macary, Marcial García Rojo, Jacques Klossa, Arvydas Laurinavi?ius, Bruce A Beckwith, Vincenzo Della Mea PhD
      Diagnostic Pathology 2011, 6(Suppl 1):S17 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Using MATLAB software with Tomcat server and Java platform for remote image analysis in pathology
      Tomasz Markiewicz
      Diagnostic Pathology 2011, 6(Suppl 1):S18 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Expanding application of digital pathology in Japan - from education, telepathology to autodiagnosis
      Yasunari Tsuchihashi
      Diagnostic Pathology 2011, 6(Suppl 1):S19 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

      Proceedings    
      Accuracy of a remote quantitative image analysis in the whole slide images
      Janina S?odkowska, Tomasz Markiewicz, Bart?omiej Grala, Wojciech Koz?owski, Wielis?aw Papierz, Katarzyna Pleskacz, Piotr Murawski
      Diagnostic Pathology 2011, 6(Suppl 1):S20 (30 March 2011)
      [Abstract] [Full text] [PDF]

       

       

      SIVQ-aided laser capture microdissection: A tool for high-throughput expression profiling

      Jason Hipp1, Jerome Cheng1, Jeffrey C. Hanson2, Wusheng Yan2, Phil Taylor3, Nan Hu2, Jaime
      Rodriguez-Canales2, Jennifer Hipp2, Michael A. Tangrea2, Michael R. Emmert-Buck2, Ulysses Balis1

      1Department of Pathology, University of Michigan School of Medicine, Division of Pathology Informatics, M4233 Med Sci I, 1301 Catherine, Ann Arbor, MI 48109-0602.

      2National Institutes of Health, National Cancer Institute, Laboratory of Pathology, Center for Cancer Research, Advanced Technology Center, Room 109, 8717 Grovemont Circle, Gaithersburg, MD 20877.

      3Division of Cancer Epidemiology and Genetics, Executive Plaza South, Room 7006, Rockville, MD 20892.

      Abstract
      Introduction: Laser capture microdissection (LCM) facilitates procurement of defined cell populations for study in the context of histopathology. The morphologic assessment step in the LCM procedure is time consuming and tedious, thus restricting the utility of the technology for large applications.

      Results: Here, we describe the use of Spatially Invariant Vector Quantization (SIVQ) for histological analysis within LCM. Using SIVQ, we selected vectors as morphologic predicates that were representative of normal epithelial or cancer cells and then searched for phenotypically similar cells across entire tissue sections. The selected cells were subsequently auto-microdissected and the recovered RNA was analyzed by expression microarray. Gene expression profiles from SIVQ–LCM and standard LCM-derived samples demonstrated highly congruous signatures, confirming the equivalence of the differing microdissection methods.

      Conclusion: SIVQ–LCM improves the workflow of microdissection in two significant ways. First, the process is transformative in that it shifts the pathologist’s role from technical execution of the entire microdissection to a limited-contact supervisory role, enabling large-scale extraction of tissue by expediting subsequent semi-autonomous identification of target cell populations. Second, this work-flow model provides an opportunity to systematically identify highly constrained cell populations and morphologically consistent regions within tissue sections. Integrating SIVQ with LCM in a single environment provides advanced capabilities for efficient and high-throughput histological-based molecular studies.


      Key words: Laser capture microdissection, microarray, Spatially Invariant Vector Quantization

      E-mail: *Ulysses J. Balis - ulysses@umich.edu
      *Corresponding author
      Received: 26 January 11 Accepted: 22 February 11 Published: 31 March 11
      DOI: 10.4103/2153-3539.78500 J Pathol Inform 2011, 2:19
      This article is available from: http://www.jpathinformatics.org/content/2/1/19
      Copyright: © 2011 Hipp J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
      reproduction in any medium, provided the original author and source are credited.


      This article may be cited as:
      Hipp J, Cheng J, Hanson JC, Yan W, Taylor P, Hu N, Rodriguez-Canales J, Hipp J, Tangrea MA, Emmert-Buck MR, Balis U. SIVQ-aided laser capture microdissection: A tool for high-throughput
      expression profiling. J Pathol Inform 2011;2:19

       

      Can vendors use the word “telepathology”?

       

      Can vendors use the word "telepathology" in marketing materials?  Few do out of concern due to lack of FDA clearance for the scanning device.  Companies based overseas are particularly reluctant and dare say the term.  Even some of the newer vendors to the space are careful to point out that their devices are for "research purposes only" and disclaimers to the effect that the devices have not been cleared by the FDA for primary interpretation are nearly universal among vendors.  

      So, manufacturers do not make a claim that their device can be used for primary H&E reads.

      Enter AccelPath which I mentioned a couple of weeks ago in a post.  Since that post, courtesy of Laboratory Economics (subscription required) they recently reported that:

      "AccelPath LLC (Westwood, MA) has partnered with the in-office lab consulting firm Triangle Biomedical Sciences (TBS-Durham, NC) and begun marketing digital pathology services to urology, gastroenterology and dermatology groups. Under the partnership, TBS will help specialty groups build in-office labs and AccelPath will install digital slide scanners. Digitized slide images will be sent electronically to AccelPath, which has contracted with the Pathology Department at the Lahey Clinic (Burlington, MA) for professional interpretations."

       On AccelPath's website they mention specifically "primary interpretations" as one of the many uses with these added value propositions:

      • Eliminate the cost, delays and logistics of shipping slides and blocks
      • Eliminate the need to recruit, hire and retain pathologists
      • Enjoy full access to AccelPath's prestigious team of U.S. based pathologists
      • Receive fastest slide-to-report service
      • Obtain 24/7 access to digital archives of all reports, requisitions and images
      • Maintain control by keeping all slides on site at all times
      • Implement our program easily with support from trained professionals

      All of this is both encouraging and a real threat with continued commoditization of pathology services.

      Laboratory Economics notes that the transaction has created the first publicly-traded company focused on two key trends in anatomic pathology (i.e., digital pathology and in-office histology labs).

      This means clinicians in-source histology for the technical component and out-source the professional component in lieu of an in-office pathologist or local pathology group.

      Apparently, they are comfortable with primary reads although I am not clear what scanner(s) are being used and how they have addressed the issue.  Presumably they have validated the technology internally and are confident in their ability to offer fast, accurate diagnoses. 

      ?The encouraging part is that this marriage between in-office labs and digital pathology with a validated system allows for other groups to replicate the model whether it is a local GI group who is going to bring histology "in house" to referring work to other pathologists from primary laboratories for primary reads.  Unmanned pathology shops with 24/7 MD support. 

      ?This may provide a completely legitimate way for pathologists to try to "get back" work that has been "lost" to in-office labs with medical director oversight of the laboratory and a TC/PC arrangement where the parties involved get paid for what they are doing rather than having employed pathologists who may not see the full PC for work that he/she has done.

      ?Is this a threat or opportunity for pathology?

      ?About AccelPath

      AccelPath was formed in October 2008 by Shekhar Wadekar, PhD, chief executive, and H. Lance Evans, MD, head of medical affairs. Wadekar has a PhD in engineering from the University of Delaware and an MBA from New York University. Evans is a board-certified pathologist and practiced hematopathology at Impath (now part of LabCorp/Genzyme Genetics).

      AccelPath was recently acquired by Technest Holdings Inc. (Bethesda, MD). Technest is a penny-stock company that trades on the OTC Bulletin Board at a current price of about 8 cents per share (as of March 15). Technest issued 86 million shares valued at roughly $6.5 million to purchase AccelPath. As a result of this reverse-buyout transaction, AccelPath members now own approximately 72.5% of Technest and Wadekar has become chief executive.

      Finnish researchers develop giant multi-user microscope

      Finnish researchers have created an innovative new microscope that responds to hand and finger gestures on a giant touch screen. Looks like the images are off of a Mirax scanner.

       

      More information on MutliTouch (English pdf).

      The 'multitouch microscope' is the fruit of collaboration between researchers from the Institute for Molecular Medicine Finland (FIMM), and the Finnish company Multitouch Ltd, who specialise in professional multitouch displays and software platforms that support multi-user environments.

      The microscope works like a giant interactive touch screen and can be operated by multiple users, bringing new opportunities to teaching and research.

      'The giant size, minimum 46 inch screen looks somewhat like an iPad on steroids,' says researcher Johan Lundin, one of the developers of the microscope. 'The sample viewing experience is like a combination of Google Maps and the user interface from the movie Minority Report.'

      The resulting user experience is an entirely new way of performing microscopy. By simply touching a giant screen, in the form of a table or even a wall-mounted screen, the user can navigate and zoom within a microscope sample in the same way as with a conventional microscope. However, using the touch control it is possible to move from the natural size of the sample to a 1,000-fold magnification, at which cells and even subcellular details can be seen.

      The microscope works by digitising biological samples using a microscopy scanner and storing them on an image server. Samples displayed on the screen are then continuously read from the server over the Internet and the size of a single sample can be up to 200 gigabytes (GB).

      It is hoped that the accessibility of the format will encourage more students to engage with microscopy. The developers think that the method will revolutionise microscopy teaching as a group of students can stand around the display together with the teacher and examine the same sample. The multitouch function of the microscope means that a whole class of students can work on one biological sample at the same time, improving student engagement.

      'The multitouch microscope brings a new dimension into interactive teaching and the learning curve is practically zero when compared to conventional microscopy which can be quite challenging for students,' explains Lundin.

      Lundin also points out that the microscope will be invaluable for scientific meetings or any 'situation where a group of users need to simultaneously view a microscopy sample, for example when a consensus needs to be reached concerning a new disease entity or a rare case.'

      The multitouch microscope builds on the success of another Finnish innovation - web-based virtual microscopy or the 'WebMicroscope', which was developed a few years ago by researchers from the University of Helsinki and the University of Tampere. This has been well received among students and is used at more than 10 European universities and in many countries for laboratory quality assurance.

      In virtual microscopy a digital copy of a sample on a glass slide is created. A virtual slide can consist of up to 50,000 separate digital images aligned into a mosaic representing the whole sample at high magnification. The image mosaic can be viewed over the Internet using a common web browser and the user can select any area or magnification as in conventional microscopy.

      The FIMM is an international research institute focusing on building a bridge from discovery to medical applications. FIMM investigates molecular mechanisms of disease using genomics and medical systems biology in order to promote human health. FIMM is a multidisciplinary institute combining high-quality science with unique patient materials, and state-of-the-art technologies.

      For more information, please visit:

      Institute for Molecular Medicine Finland (FIMM):
      http://www.fimm.fi

      To view a presentation on the multitouch microscope click here:
      http://www.youtube.com/user/multitouchfi?feature=mhum#p/u/12/ihaM3DvyUHE

      Category: Miscellaneous
      Data Source Provider: Institute for Molecular Medicine Finland (FIMM)
      Document Reference: Based on information provided by the Institute for Molecular Medicine Finland (FIMM)
      Subject Index: Education, Training; Innovation, Technology Transfer; Life Sciences; Medicine, Health; Scientific Research

      Armed Forces Institute of Pathology Mission Ends; Joint Pathology Center to Open

      In Beyond Good and Evil, not the PlayStation or Xbox game, but rather the completely unrelated book by Friedrich Nietzsche, he writes, "Digressions, objections, delight in mockery, carefree mistrust are signs of health; everything unconditional belongs in pathology."

      If true and everything unconditional does belong in pathology that at some point in time between 1862 and the end of March 2011 it probably was first described or studied, analyzed, demonstrated, photographed, archived, taught and/or catalogued with like and compared with similar and dissimilar forms of itself at the Armed Forces Institute of Pathology (AFIP) in Washington, DC.   

      Readers will know that I have been following the closing of AFIP since the 2005 Base Realignment and Closure (BRAC) Commission recommended disestablishment of the AFIP.  Since the report was released in May of 2005 after multiple political wranglings the AFIP will disestablish and permanently close by mid-September this year. The Institute ceased all education programs on October 1, 2010. Additionally on Oct. 1, the AFIP stopped accepting nonfederal civilian consultation cases. This action was followed by cessation of all research on December 15, 2010.  And on March 31 what remains of their consultation mission will come to a close when the AFIP ceases accepting cases for military members and veterans. All three AFIP missions, and the DoD Tissue Repository mission, will then become the responsibility of DOD’s new Joint Pathology Center.

      The AFIP will soon release a book detailing the legacy of the AFIP.  You can see portions of it in the last AFIP Letter recently published.

      On April 1, the newly formed DOD Joint Pathology Center (JPC) will beginning receiving miltary and VA cases for consultation to carry on that role performed by AFIP.  The JPC will also have oversight over the vast tissue repository and add its research and educational offerings as staffing allows.  Perhaps they may one day begin to accept civilian consultations as well.

      The museum that was housed in the AFIP building will also move to a new location over the next several months and plans on re-opening in the fall.  Check out their Facebook page to see when the exhibits will re-open in their new home.

      Tips and Tricks for Scanning and Viewing Digital Slides – Aperio Webinar April 27th

      This should be a good one.  Ole Eichhorn is a good speaker who has a way of making technical issues simple and user friendly

      Wednesday, April 27, 2011

      7:00 am Pacific Time, 10:00 am Eastern Time 
      (3:00 pm London GMT / 9:00 am Mexico City Standard Time) 

       OR

       
      4:00 pm Pacific Time, 7:00 pm Eastern Time
      (8:00 am Japan Time / 9:00 am Australia EST April 28)  

      Presenter:
      Ole Eichhorn, Chief Technology Officer, Aperio 

      In this 60-minute, complimentary webinar, we will present simple tips for getting the most out of your digital pathology system, including ScanScope scanners, Spectrum Plus, the latest Spectrum Plus release, and the ImageScope and WebScope viewing tools. 

      Topics include:

      • Ways to improve your scan quality
      • Mouse and keyboard shortcuts
      • Viewing navigation: panning and zooming through digital slides
      • Saving and bookmarking specific views of slides
      • Annotation tips and techniques
      • Interfacing to third-party image tools
      • A look at Spectrum Release 11

      This webinar will cover many of the tips we’ve posted online at blog.aperio.com/chalk-tip-index.html. Please visit blog.aperio.com often for Pathology News and ongoing tips and techniques.

      To register for the 7am PDT session, click here.https://aperio.webex.com/aperio/onstage/g.php?t=a&d=489644732
      To register for the 4pm PDT session, click here
      https://aperio.webex.com/aperio/onstage/g.php?t=a&d=481795953

      You may also register by visiting the Aperio Events page.

      You will receive a confirmation email upon registration with a web link that will lead you to the online event. Simply visit the link at the assigned time. The session is secure and easy to access. If you have any questions or would like additional information, please contact the Aperio Events Team at events@aperio.com or 760.539.1192.